Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Work In Process (2016 - 2025)

Historic Work In Process for Heron Therapeutics (HRTX) over the last 10 years, with Q3 2025 value amounting to $26.3 million.

  • Heron Therapeutics' Work In Process rose 4354.29% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.3 million, marking a year-over-year increase of 4354.29%. This contributed to the annual value of $27.2 million for FY2024, which is 8687.29% up from last year.
  • Latest data reveals that Heron Therapeutics reported Work In Process of $26.3 million as of Q3 2025, which was up 4354.29% from $26.1 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Work In Process registered a high of $29.0 million during Q1 2025, and its lowest value of $9.0 million during Q2 2023.
  • Moreover, its 5-year median value for Work In Process was $16.4 million (2023), whereas its average is $17.9 million.
  • Its Work In Process has fluctuated over the past 5 years, first surged by 20575.43% in 2021, then plummeted by 5517.77% in 2023.
  • Over the past 5 years, Heron Therapeutics' Work In Process (Quarter) stood at $20.9 million in 2021, then decreased by 1.01% to $20.7 million in 2022, then decreased by 29.79% to $14.6 million in 2023, then surged by 86.87% to $27.2 million in 2024, then decreased by 3.12% to $26.3 million in 2025.
  • Its Work In Process stands at $26.3 million for Q3 2025, versus $26.1 million for Q2 2025 and $29.0 million for Q1 2025.